[S-8 POS] Unity Biotechnology, Inc. SEC Filing

Rhea-AI Filing Summary

Unity Biotechnology filed Post-Effective Amendment No. 1 to terminate the effectiveness of multiple Form S-8 registration statements and remove from registration any unsold shares of its common stock previously registered for various equity plans. The amendment lists ten S-8 registrations (from 2018 through 2025) and the original share amounts for each plan, and states the registratio ns are amended to reflect deregistration of all unsold securities.

Insights

Financial Analyst

TL;DR Unity deregistered unsold S-8 shares across multiple employee plans, a routine housekeeping filing with limited investor impact.

This filing terminates the effectiveness of ten S-8 registration statements and removes any unsold shares that had been registered for employee equity plans and the employee stock purchase plan. The action is administrative and does not, by itself, change outstanding shares or grant rights; it simply removes the ability to issue those specific registered but unsold shares under the listed registration statements.

Corporate Governance Expert

TL;DR The amendment is a procedural deregistration of unsold plan shares and reflects no disclosed governance or control changes.

The company specifies each S-8 by file number and original registered share amounts for various incentive and inducement plans. The filing notes that numbers do not reflect interim corporate actions. No executive departures, plan amendments, or transfers of material assets are disclosed; this is consistent with routine post-effective amendment practice.

As filed with the Securities and Exchange Commission on August 25, 2025

Registration No. 333-224726

Registration No. 333-230086

Registration No. 333-237088

Registration No. 333-237474

Registration No. 333-250926

Registration No. 333-254619

Registration No. 333-263576

Registration No. 333-270567

Registration No. 333-278679

Registration No. 333-285649

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-224726

POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-230086

POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-237088

POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-237474

POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-250926

POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-254619

POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-263576

POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-270567

POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-278679

POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-285649

FORM S-8

REGISTRATION STATEMENT

Under

The Securities Act of 1933

UNITY BIOTECHNOLOGY, INC.

(Exact name of registrant as specified in its charter)

Delaware		26-4726035
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification Number)

124 Washington Street, Suite 101

Foxborough, Massachusetts 02035

(508) 543-1720

(Address of Principal Executive Offices)

Unity Biotechnology, Inc. 2013 Equity Incentive Plan

Unity Biotechnology, Inc. 2018 Incentive Award Plan

Unity Biotechnology, Inc. 2018 Employee Stock Purchase Plan

Unity Biotechnology, Inc. 2020 Employment Inducement Incentive Award Plan

(Full Title of the Plans)

Craig R. Jalbert

President, Secretary, and Director

Unity Biotechnology, Inc.

124 Washington Street, Suite 101

Foxborough, Massachusetts 02035

(508) 543-1720

(Name and address, including zip code, and telephone number, including area code, of agent for service)

Copies to:

Erica Kassman

Latham & Watkins LLP

140 Scott Drive

Menlo Park, CA 94025

Telephone: (650) 328-4600

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer		☐		Accelerated filer		☐
Non-accelerated filer		☒		Smaller reporting company		☒
				Emerging growth company		☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

EXPLANATORY NOTE

DEREGISTRATION OF SECURITIES

This Post-Effective Amendment No. 1 (“Post-Effective Amendment No. 1”) filed by Unity Biotechnology, Inc., a Delaware corporation (the “Company”), removes from registration all shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), registered under the following Registration Statements on Form S-8 (each a “Registration Statement” and, collectively, the “Registration Statements”) filed with the U.S. Securities and Exchange Commission (the “Commission”) that remain unsold thereunder:

• Registration Statement on Form S-8 (No. 333-224726), filed with the Commission on May 7, 2018, pertaining to the registration of (i) 5,293,729 shares of the Company’s Common Stock under the Company’s 2013 Equity Incentive Plan and 2018 Incentive Award Plan, (ii) 3,330,530 shares of the Company’s Common Stock under the Company’s 2018 Incentive Award Plan, and (iii) 536,242 shares of the Company’s Common Stock under the Company’s 2018 Employee Stock Purchase Plan.

• Registration Statement on Form S-8 (No. 333-230086), filed with the Commission on March 6, 2019, pertaining to the registration of (i) 2,125,510 shares of the Company’s Common Stock under the Company’s 2018 Incentive Award Plan, and (ii) 424,143 shares of the Company’s Common Stock under the Company’s 2018 Employee Stock Purchase Plan.

• Registration Statement on Form S-8 (No. 333-237088), filed with the Commission on March 11, 2020, pertaining to the registration of (i) 2,361,841 shares of the Company’s Common Stock under the Company’s 2018 Incentive Award Plan, and (ii) 472,271 shares of the Company’s Common Stock under the Company’s 2018 Employee Stock Purchase Plan.

• Registration Statement on Form S-8 (No. 333-237474), filed with the Commission on March 30, 2020, pertaining to the registration of 1,100,000 shares of the Company’s Common Stock under the Company’s 2020 Employment Inducement Incentive Award Plan.

• Registration Statement on Form S-8 (No. 333-250926), filed with the Commission on November 24, 2020, pertaining to the registration of 1,500,000 shares of the Company’s Common Stock under the Company’s 2020 Employment Inducement Incentive Award Plan, as amended.

• Registration Statement on Form S-8 (No. 333-254619), filed with the Commission on March 23, 2021, pertaining to the registration of (i) 2,675,309 shares of the Company’s Common Stock under the Company’s 2018 Incentive Award Plan, and (ii) 532,480 shares of the Company’s Common Stock under the Company’s 2018 Employee Stock Purchase Plan.

• Registration Statement on Form S-8 (No. 333-263576), filed with the Commission on March 15, 2022, pertaining to the registration of (i) 3,182,965 shares of the Company’s Common Stock under the Company’s 2018 Incentive Award Plan, and (ii) 629,919 shares of the Company’s Common Stock under the Company’s 2018 Employee Stock Purchase Plan.

• Registration Statement on Form S-8 (No. 333-270567), filed with the Commission on March 15, 2023, pertaining to the registration of (i) 710,765 shares of the Company’s Common Stock under the Company’s 2018 Incentive Award Plan, (ii) 142,153 shares of the Company’s Common Stock under the Company’s 2018 Employee Stock Purchase Plan, and (iii) 300,000 shares of the Company’s Common Stock under the Company’s 2020 Employment Inducement Incentive Award Plan, as amended.

• Registration Statement on Form S-8 (No. 333-278679), filed with the Commission on April 15, 2024, pertaining to the registration of (i) 839,248 shares of the Company’s Common Stock under the Company’s 2018 Incentive Award Plan, and (ii) 167,849 shares of the Company’s Common Stock under the 2018 Employee Stock Purchase Plan.

• Registration Statement on Form S-8 (No. 333-285649), filed with the Commission on March 7, 2025, pertaining to the registration of (i) 843,260 shares of the Company’s Common Stock under the Company’s 2018 Incentive Award Plan, and (ii) 168,652 shares of the Company’s Common Stock under the Company’s 2018 Employee Stock Purchase Plan.

As previously reported on June 27, 2025, the board of directors of the Company: (i) determined that it is in the best interests of the Company and its stakeholders that the Company be liquidated and dissolved in accordance with the Delaware General Corporation Law pursuant to a Plan of Complete Liquidation and Dissolution (the “Dissolution”); and (ii) approved seeking stockholder approval to proceed with the Dissolution pursuant to Delaware law at a special meeting of stockholders and, if approved by stockholders, file a Certificate of Dissolution with the Secretary of State of the State of Delaware. In connection with the foregoing, the Company has determined to terminate the offerings of securities under the Registration Statements. Accordingly, the Company is filing this Post-Effective Amendment No. 1 to terminate the effectiveness of the Registration Statements, and, in accordance with the undertakings made by the Company in the Registration Statements, to remove from registration any and all of the securities that remain unsold under the Registration Statements as of the date hereof. The Registration Statements are hereby amended, as appropriate, to reflect the deregistration of all such securities. Note that the numbers of securities listed above do not take into account any applicable corporate actions, such as stock splits, that may have been taken in the interim.

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Post-Effective Amendment No. 1 to the Registration Statements to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Foxborough in the Commonwealth of Massachusetts, on August 25, 2025.

UNITY BIOTECHNOLOGY, INC.
By:		/s/ Craig R. Jalbert
		Title: President, Secretary, and Director

No other person is required to sign this Post-Effective Amendment No. 1 to the Registration Statements on Form S-8 in reliance on Rule 478 of the Securities Act of 1933, as amended.

FAQ

What did Unity Biotechnology (UBX) file in this S-8 Post-Effective Amendment?

The company filed Post-Effective Amendment No. 1 to terminate effectiveness of multiple Form S-8 registration statements and remove any unsold shares registered under those statements.

Which registration statements were affected by Unity's filing?

Ten S-8 registration statements are listed by file number, covering filings from 2018 through 2025 (including Nos. 333-224726 through 333-285649).

Which types of equity plans were involved in the deregistration?

The filing references shares registered under the 2013 Equity Incentive Plan, the 2018 Incentive Award Plan, the 2020 Employment Inducement Incentive Award Plan, and the 2018 Employee Stock Purchase Plan.

Does this filing change outstanding shares or equity awards already granted?

No. The amendment removes unsold registered shares from the registration statements; it does not, by itself, alter already issued shares or granted awards.

Are the specific numbers of deregistered shares provided?

The filing lists the original numbers registered under each S-8, but notes those figures do not account for interim corporate actions such as stock splits.